一个经典实体瘤靶点的“复兴”之战

丁香园 Insight 数据库
Oct 30, 2025

在抗癌治疗的漫长征程中,HER2 是一个闪耀了四十年的经典靶点。它曾被视为“死亡判决”,却又因曲妥珠单抗、德曲妥珠单抗等划时代药物的诞生而成为巨头林立、管线密布的红海战场。如今,多元化技术类型、联用策略、攻克耐药等不同维度的大胆探索,正在 HER2 的疆域里激烈上演,前方的战局依然充满变数。国内研发热潮涌动中国药企在 HER2 靶点领域正展现出蓬勃的创新活力。今年,恒瑞的瑞康曲妥珠单抗和科伦博泰的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10